Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.57 |
| ▸ | CA1 | P00915 | 5/20 | 0.57 |
| ▸ | CA2 | P00918 | 5/20 | 0.57 |
| ▸ | CA9 | Q16790 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TYMP | P19971 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 7/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17783197 | 0.98 | CA12 (0.56) | CA12CA1CA2CA9LMNA | |
| SCHEMBL15710355 | 0.98 | CA12 (0.56) | CA12CA1CA2CA9LMNA | |
| SCHEMBL28572545 | 0.98 | CA12 (0.56) | CA12CA1CA2CA9LMNA | |
| SCHEMBL28588942 | 0.98 | CA12 (0.56) | CA12CA1CA2CA9LMNA | |
| SCHEMBL4360078 | 0.95 | CA12 (0.58) | CA12CA1CA2CA9LMNA | |
| Hydrochloric Acid SCHEMBL31250585 | 0.94 | CA12 (0.57) | CA12CA1CA2CA9LMNA | |
| SCHEMBL8431954 | 0.88 | CA12 (0.61) | CA12CA1CA2CA9LMNA | |
| Trifluoroacetic Acid SCHEMBL29174403 | 0.88 | CA12 (0.47) | CA12CA1CA2CA9LMNA | |
| Trifluoroacetic Acid SCHEMBL29174409 | 0.87 | CA12 (0.46) | CA12CA1CA2CA9LMNA | |
| Hydrochloric Acid SCHEMBL12004636 | 0.87 | CA12 (0.60) | CA12CA1CA2CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113350489-A | Glucose responsive insulin delivery system using hypoxia sensitive nanocomposite material | 北卡罗来纳州立大学 | 2021-09-07 | — | — | CN | disclosed |
| CN-107530296-B | Glucose responsive insulin delivery system using hypoxia sensitive nanocomposite material | 北卡罗来纳州立大学 | 2021-06-22 | — | — | CN | disclosed |
| CN-107530296-A | Glucose responsive insulin delivery system using hypoxia sensitive nanocomposite material | 北卡罗来纳州立大学 | 2018-01-02 | — | — | CN | disclosed |
| US-7618986-B2 | Method of treating latent tuberculosis | EVANSTON NORTHWESTERN HEALTHCARE (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1613613-A4 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2009-03-25 | — | — | EP | disclosed |
| US-20080076797-A1 | Method of Treating Latent Tuberculosis | EVANSTON NORTHWESTERN HEALTHCARE (US) | 2008-03-27 | — | — | US | disclosed |
| EP-1613613-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004091518-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076797-A1 | Method of Treating Latent Tuberculosis | SDHA, NDUFB7, DUT | CA12 4047/4885CA1 4698/4885CA2 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.